Skip to contentP
Petros Pharmaceuticals, Inc.
P
PTPIPetros Pharmaceuticals, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$725.40K$725.40Kderivedno prior Q4 2023 on file Net Income-$9.27M-$9.27MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$460,646N/M Operating Incomederived-$577,555N/M Operating Cash Flowderived$965,405N/M Free Cash Flowderived$959,956— Margins · derivedGross margin63.5%
Operating margin-79.6%
Net margin-1278.4%
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end